Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: The merger gives HAB Pharma a bigger scale story: a cleaner corporate structure, more manufacturing capacity, and a stronger platform to sell specialty products in more ...
